EU/US Properties Organoleptics Cosmetics Suppliers Safety Safety in use Safety references References Other Blenders Uses Occurrence Synonyms Articles Notes
 

ipriflavone
4H-1-benzopyran-4-one, 7-(1-methylethoxy)-3-phenyl-

Supplier Sponsors

Name:3-phenyl-7-propan-2-yloxychromen-4-one
CAS Number: 35212-22-7Picture of molecule3D/inchi
FDA UNII: 80BJ7WN25Z
Nikkaji Web:J19.468I
Beilstein Number:4754346
MDL:MFCD00221719
XlogP3-AA:4.00 (est)
Molecular Weight:280.32312000
Formula:C18 H16 O3
BioActivity Summary:listing
NMR Predictor:Predict (works with chrome, Edge or firefox)
Category:special dietary and nutritional additives
 
US / EU / FDA / JECFA / FEMA / FLAVIS / Scholar / Patent Information:
Google Scholar:Search
Google Books:Search
Google Scholar: with word "volatile"Search
Google Scholar: with word "flavor"Search
Google Scholar: with word "odor"Search
Google Patents:Search
US Patents:Search
EU Patents:Search
Pubchem Patents:Search
PubMed:Search
NCBI:Search
 
Physical Properties:
Assay: 95.00 to 100.00
Food Chemicals Codex Listed: No
Boiling Point: 435.85 °C. @ 760.00 mm Hg (est)
Flash Point: 409.00 °F. TCC ( 209.30 °C. ) (est)
logP (o/w): 4.245 (est)
Soluble in:
 water, 2.301 mg/L @ 25 °C (est)
 
Organoleptic Properties:
Odor and/or flavor descriptions from others (if found).
 
Cosmetic Information:
None found
 
Suppliers:
AIDP
Ipriflavone 99% min.
BOC Sciences
For experimental / research use only.
Ipriflavone >98%
Odor: characteristic
Use: Ipriflavone (7-Isopropoxyisoflavon) is used to inhibit bone resorption.
ExtraSynthese
For experimental / research use only.
Ipriflavone (HPLC) ≥90%
Jiangyin Healthway
Ipriflavone
New functional food ingredients
Maypro Industries
Ipriflavone
Sabinsa Corporation
Ipriflavone
Shaanxi Y-Herb Biotechnology
White Fine Ipriflavone Monomer Powder CAS 35212-22-7 For Osteoporosis Bone Care
Sigma-Aldrich: Aldrich
For experimental / research use only.
7-IsoPropoxy-3-phenyl-4H-1-benzopyran-4-one 97%
sds
TCI AMERICA
For experimental / research use only.
Ipriflavone >98.0%(GC)
sds
 
Safety Information:
Preferred SDS: View
 
Hazards identification
 
Classification of the substance or mixture
GHS Classification in accordance with 29 CFR 1910 (OSHA HCS)
None found.
GHS Label elements, including precautionary statements
 
Pictogram
 
Hazard statement(s)
None found.
Precautionary statement(s)
None found.
Oral/Parenteral Toxicity:
intraperitoneal-mouse LD50 > 10000 mg/kg
Iyakuhin Kenkyu. Study of Medical Supplies. Vol. 20, Pg. 228, 1989.

oral-mouse LD50 3185 mg/kg
Khimiko-Farmatsevticheskii Zhurnal. Chemical Pharmaceutical Journal. For English translation, see PCJOAU. Vol. 24(9), Pg. 38, 1990.

intraperitoneal-rat LD50 > 10000 mg/kg
Iyakuhin Kenkyu. Study of Medical Supplies. Vol. 20, Pg. 228, 1989.

oral-rat LD50 > 2500 mg/kg
Iyakuhin Kenkyu. Study of Medical Supplies. Vol. 20, Pg. 228, 1989.

Dermal Toxicity:
subcutaneous-mouse LD50 > 2500 mg/kg
Iyakuhin Kenkyu. Study of Medical Supplies. Vol. 20, Pg. 228, 1989.

subcutaneous-rat LD50 > 2500 mg/kg
Iyakuhin Kenkyu. Study of Medical Supplies. Vol. 20, Pg. 228, 1989.

Inhalation Toxicity:
Not determined
 
Safety in Use Information:
Category:
special dietary and nutritional additives
Recommendation for ipriflavone usage levels up to:
 not for fragrance use.
 
Recommendation for ipriflavone flavor usage levels up to:
 not for flavor use.
 
Safety References:
EPI System: View
Chemical Carcinogenesis Research Information System:Search
AIDS Citations:Search
Cancer Citations:Search
Toxicology Citations:Search
EPA ACToR:Toxicology Data
EPA Substance Registry Services (SRS):Registry
Laboratory Chemical Safety Summary :3747
National Institute of Allergy and Infectious Diseases:Data
WGK Germany:2
3-phenyl-7-propan-2-yloxychromen-4-one
Chemidplus:0035212227
RTECS:DJ3100500 for cas# 35212-22-7
 
References:
 3-phenyl-7-propan-2-yloxychromen-4-one
NIST Chemistry WebBook:Search Inchi
Pubchem (cid):3747
Pubchem (sid):135029160
 
Other Information:
(IUPAC):Atomic Weights of the Elements 2011 (pdf)
Videos:The Periodic Table of Videos
tgsc:Atomic Weights use for this web site
(IUPAC):Periodic Table of the Elements
CHEBI:View
CHEMBL:View
KEGG (GenomeNet):D01338
HMDB (The Human Metabolome Database):HMDB32987
FooDB:FDB010976
Export Tariff Code:2932.99.7000
FDA Listing of Food Additive Status:View
ChemSpider:View
Wikipedia:View
 
Potential Blenders and core components note
None Found
 
Potential Uses:
None Found
 
Occurrence (nature, food, other):note
 not found in nature
 
Synonyms:
4H-1-benzopyran-4-one, 7-(1-methylethoxy)-3-phenyl-
 iprosten
7-(1-methylethoxy)-3-phenyl-4H-1-benzopyran-4-one
7-(methylethoxy)-3-phenylchromen-4-one
 osteochin
 osteofix
 osteoquine
3-phenyl-7-(propan-2-yloxy)-4H-chromen-4-one
3-phenyl-7-propan-2-yloxychromen-4-one
7-isopropoxy-3-phenyl-4H-1-benzopyran-4-one
7-isopropoxy-3-phenyl-4H-chromen-4-one
7-isopropoxy-3-phenyl-chromen-4-one
7-isopropoxy-3-phenylchromone
7-isopropoxyisoflavone
 quinogin
 yambolap
 

Articles:

PubMed:Chinese herbal medicines for treating osteoporosis.
PubMed:Ipriflavone reverses the adverse effects of a low-calcium diet on the histology of the tibia in caged layers.
PubMed:Antimutagenic activity of ipriflavone against the DNA-damage induced by cyclophosphamide in mice.
PubMed:The neuroprotective effects of ipriflavone against H ₂O ₂ and amyloid beta induced toxicity in human neuroblastoma SH-SY5Y cells.
PubMed:Inhibitory effects of isoflavonoids on rat prostate testosterone 5α-reductase.
PubMed:Synthesis of aminoalkoxy substituted 4,5-diphenylisoxazole derivatives as potential anti-osteoporotic agents.
PubMed:[Effect of ipriflavone on Wistar rats and their litters].
PubMed:Mutagenicity of ipriflavone in vivo and in vitro.
PubMed:Determination of ipriflavone in human plasma by LC-MS and its application in a pharmacokinetic study.
PubMed:The significance of soy protein and soy bioactive compounds in the prophylaxis and treatment of osteoporosis.
PubMed:TAK-778 induces osteogenesis in ovariectomized rats via an estrogen receptor-dependent pathway.
PubMed:Functionalizing mesoporous bioglasses for long-term anti-osteoporotic drug delivery.
PubMed:Identification of Hedgehog signaling inhibitors with relevant human exposure by small molecule screening.
PubMed:Anabolics in osteoporosis: the emerging therapeutic tool.
PubMed:Pharmacokinetics of ipriflavone and its two metabolites, M1 and M5, after the intravenous and oral administration of ipriflavone to rat model of diabetes mellitus induced by streptozotocin.
PubMed:Effects of ipriflavone on postmenopausal syndrome and osteoporosis.
PubMed:Determination of the anti-osteoporosis drug ipriflavone in pharmaceutical formulation by stripping voltammetric and chromatographic methods.
PubMed:Ipriflavone pharmacokinetics in mutant Nagase analbuminemic rats.
PubMed:[Effect of ipriflavone on growth and blood testosterone level in male rats].
PubMed:Synthesis and anti-osteoporotic evaluation of certain 3-amino-2-hydroxypropoxyisoflavone derivatives.
PubMed:Role of phytochemicals in the prevention of menopausal bone loss: evidence from in vitro and in vivo, human interventional and pharma-cokinetic studies.
PubMed:The combination of genistin and ipriflavone prevents mammary tumorigenesis and modulates lipid profile.
PubMed:Effects of estrogen and estrogenic compounds on cognition in ovariectomized rats.
PubMed:Effects of E. Coli lipopolysaccharide on the pharmacokinetics of ipriflavone and its metabolites, M1 and M5, after intravenous and oral administration of ipriflavone to rats: decreased metabolism of ipriflavone due to decreased expression of hepatic CYP1A2 and 2C11.
PubMed:Effects of phytoestrogen on mitochondrial structure and function of hippocampal CA1 region of ovariectomized rats.
PubMed:WITHDRAWN: The combination of genistin and ipriflavone prevents mammary tumorigenesis and modulates lipid profile.
PubMed:Potential ipriflavone and warfarin interaction.
PubMed:Effects of water deprivation for 72 h on the pharmacokinetics of ipriflavone in rats.
PubMed:Effects of intravenous zoledronic acid once yearly on bone remodeling and bone structure.
PubMed:Characterization of cytochrome P450s mediating ipriflavone metabolism in human liver microsomes.
PubMed:Effects of ipriflavone on caged layer bone metabolism in vitro and in vivo.
PubMed:Effects of ipriflavone on augmented bone using a guided bone regeneration procedure.
PubMed:Complementary medicine for prostate cancer: effects of soy and fat consumption.
PubMed:Mechanism of increased coxsackie and adenovirus receptor gene expression and adenovirus uptake by phytoestrogen and histone deacetylase inhibitor in human bladder cancer cells and the potential clinical application.
PubMed:Pharmacokinetic changes of ipriflavone in rats with acute renal failure induced by uranyl nitrate.
PubMed:Soy protein supplementation does not cause lymphocytopenia in postmenopausal women.
PubMed:Effects of enzyme inducers and inhibitors on the pharmacokinetics of intravenous ipriflavone in rats.
PubMed:Ipriflavone modulates IGF-I but is unable to restore bone in rats.
PubMed:Diagnosis and treatment of osteoporosis in Brazil.
PubMed:Expression profiling of the estrogen responsive genes in response to phytoestrogens using a customized DNA microarray.
PubMed:The effect of oral ipriflavone on the rat mandible during growth.
PubMed:Studies on the interactions between drugs and estrogen. III. Inhibitory effects of 29 drugs reported to induce gynecomastia on the glucuronidation of estradiol.
PubMed:Inhibition of COX isoforms by nutraceuticals.
PubMed:The effect of two dietary and a synthetic phytoestrogen on transepithelial calcium transport in human intestinal-like Caco-2 cells.
PubMed:Soy isoflavones prevent the ovarian hormone deficiency-associated rise in leukocytes in rats.
PubMed:Induction of apoptosis in cultured rat gastric epithelial cells by ipriflavone: comparison with indomethacin.
PubMed:[Abnormality of bone mineral metabolism in type 2 diabetes mellitus].
PubMed:TAK-778 enhances osteoblast differentiation of human bone marrow cells via an estrogen-receptor-dependent pathway.
PubMed:[Interaction between ipriflavone and other drugs in metabolism in vitro].
PubMed:[Glucuronidation and in vitro interaction of Ginkgo flavonoids with other drugs].
PubMed:[Dietary phytoestrogen and its potential benefits in adult human health].
PubMed:Studies on the effects of biomedicinal agents on serum concentration of Ca2+, P and ALP activity in osteoporosis-induced rats.
PubMed:Promoting effect of kaempferol on the differentiation and mineralization of murine pre-osteoblastic cell line MC3T3-E1.
PubMed:PLGA microspheres for oral osteopenia treatment: preliminary "in vitro"/"in vivo" evaluation.
PubMed:[Synthesis of benzodihydropyran derivatives and evaluation of their preliminary biological activities on bone and vascular tissues].
PubMed:Periodontal delivery of ipriflavone: new chitosan/PLGA film delivery system for a lipophilic drug.
PubMed:Use of alternative and complementary medicine in menopause.
PubMed:2002 clinical practice guidelines for the diagnosis and management of osteoporosis in Canada.
PubMed:Effects of Siberian ginseng extract and ipriflavone on the development of glucocorticoid-induced osteoporosis.
PubMed:Ipriflavone inhibits osteolytic bone metastasis of human breast cancer cells in a nude mouse model.
PubMed:Effects of ipriflavone on bone augmentation within a titanium cap in rabbit calvaria.
PubMed:[Ipriflavone in the treatment of osteoporosis].
PubMed:[Comparative analyses on osteoporosis guidelines in Japan, EU and USA].
PubMed:Complementary therapies for reducing the risk of osteoporosis in patients receiving luteinizing hormone-releasing hormone treatment/orchiectomy for prostate cancer: a review and assessment of the need for more research.
PubMed:Update on natural product--drug interactions.
PubMed:Pharmacokinetics of ipriflavone, an isoflavone derivative, after intravenous and oral administration to rats hepatic and intestinal first-pass effects.
PubMed:[Osteoquine application in complex treatment of the diabetic foot].
PubMed:Paget's disease of the spine and its management.
PubMed:Effects of ipriflavone on bone loss following a bilateral ovariectomy and menopause: a randomized placebo-controlled study.
PubMed:Ipriflavone and osteoporosis.
PubMed:Clinical effects of phytoestrogens.
PubMed:Rapid improvement of osteomalacia by treatment in a case with Sjögren's syndrome, rheumatoid arthritis and renal tubular acidosis type 1.
PubMed:Efficacy of ipriflavone in preventing adverse effects of leuprolide.
PubMed:Ipriflavone not effective for osteoporosis.
PubMed:The in vitro biosynthesis and stability measurement with agyl-glycuronide isoformes of the main metabolite of ipriflavone.
PubMed:A review of the evidence for the use of phytoestrogens as a replacement for traditional estrogen replacement therapy.
PubMed:Preparation and dissolution property of ipriflavone solid dispersion.
PubMed:Pharmacokinetics of intragastric ipriflavone solid dispersion in rats.
PubMed:Ipriflavone in the treatment of postmenopausal osteoporosis: a randomized controlled trial.
PubMed:Pharmacokinetics and tissue distribution of ipriflavone, an isoflavone derivative, after intravenous administration to rabbits.
PubMed:The effect of an ipriflavone-containing supplement on urinary N-linked telopeptide levels in postmenopausal women.
PubMed:Phytoestrogens as hormone replacement therapy: an evidence-based approach.
PubMed:Ipriflavone, a synthetic phytoestrogen, enhances intestinal calcium transport in vitro.
PubMed:Ipriflavone.
PubMed:Evidence of type II estrogen receptor in human osteoblast-like cells.
PubMed:Stability, blood partition and plasma protein binding of ipriflavone, an isoflavone derivative.
PubMed:Soyfoods, soybean isoflavones, and bone health: a brief overview.
PubMed:Alternative therapies for menopause.
PubMed:Abnormal bone and calcium metabolism in patients after stroke.
PubMed:The synthetic phytoestrogen, ipriflavone, and estrogen prevent bone loss by different mechanisms.
PubMed:Comparison of antiresorptive activities of ipriflavone, an isoflavone derivative, and elcatonin, an eel carbocalcitonin.
PubMed:Treatment of osteoporosis: where are we and where are we going to.
PubMed:Effect of ipriflavone on bone in elderly hemiplegic stroke patients with hypovitaminosis D.
PubMed:Isoflavones and postmenopausal bone health: a viable alternative to estrogen therapy?
PubMed:Legumes and soybeans: overview of their nutritional profiles and health effects.
PubMed:Effects of 1-year ipriflavone treatment on lumbar bone mineral density and bone metabolic markers in postmenopausal women with low bone mass.
PubMed:Low-frequency acoustic sweep monitoring of bone integrity and osteoporosis.
PubMed:Ipriflavone down-regulates endothelin receptor levels during differentiation of rat calvarial osteoblast-like cells.
PubMed:A case of femoral neck fracture in a patient with severe testosterone deficiency.
PubMed:Oral ipriflavone (7-isopropoxy-isoflavone) treatment for elderly patients with resistant acute leukemias.
PubMed:Synthesis of novel 2-benzothiopyran and 3-benzothiepin derivatives and their stimulatory effect on bone formation.
PubMed:Ipriflavone: an important bone-building isoflavone.
PubMed:Phytoestrogens and human health effects: weighing up the current evidence.
PubMed:Interaction of estrogenic chemicals and phytoestrogens with estrogen receptor beta.
PubMed:Effects of ipriflavone on perialveolar bone formation.
PubMed:Therapeutic potential of selective estrogen receptor modulators.
PubMed:Comparative bioavailability of two oral formulations of ipriflavone in healthy volunteers at steady-state. Evaluation of two different dosage schemes.
PubMed:Treatment of bone loss in oophorectomized women with a combination of ipriflavone and conjugated equine estrogen.
PubMed:Evaluation of the drug therapy for established osteoporosis by dual-energy x-ray absorptiometry.
PubMed:Effect of ipriflavone--a synthetic derivative of natural isoflavones--on bone mass loss in the early years after menopause.
PubMed:Growth-inhibitory effect of tamoxifen and quercetin and presence of type II estrogen binding sites in human laryngeal cancer cell lines and primary laryngeal tumors.
PubMed:Therapy for osteoporosis. Miscellaneous and experimental agents.
PubMed:[Ipriflavone].
PubMed:Gastrojejunal fistula caused by gastric ulcer.
PubMed:[Diagnosis, therapy and nutrition management of osteoporosis].
PubMed:Ipriflavone as an inhibitor of human cytochrome P450 enzymes.
PubMed:Culture of stromal cells derived from medullary cavity of human long bone in the presence of 1,25-dihydroxyvitamin D3, recombinant human bone morphogenetic protein-2, or ipriflavone.
PubMed:Determination of a isoflavone derivative, ipriflavone, and its metabolites, M1 and M5, in rat plasma, urine, and tissue homogenate by high-performance liquid chromatography.
PubMed:[Experience with ipriflavone therapy in postmenopausal osteoporosis].
PubMed:Effects of combined low dose of the isoflavone derivative ipriflavone and estrogen replacement on bone mineral density and metabolism in postmenopausal women.
PubMed:Bone density changes in postmenopausal women with the administration of ipriflavone alone or in association with low-dose ERT.
PubMed:A double blind, placebo-controlled trial of ipriflavone for prevention of postmenopausal spinal bone loss.
PubMed:Pharmacokinetics of ipriflavone and metabolites after oral administration of a corn-oil suspension relative to the Osteofix tablet.
PubMed:Synthesis and bone resorption effect of alkoxy-substituted xanthones.
PubMed:Interaction with type II estrogen binding sites and antiproliferative activity of tamoxifen and quercetin in human non-small-cell lung cancer.
PubMed:[High performance liquid chromatographic method for the determination of ipriflavone in serum and its pharmacokinetic study in healthy volunteers].
PubMed:Integrated pharmacokinetic and metabolic modeling of ipriflavone and metabolites after oral administration.
PubMed:[Postmenopausal osteoporosis: therapeutic approaches].
PubMed:Daidzein stimulation of bone resorption in pit formation assay.
PubMed:Advanced glycation end products enhance osteoclast-induced bone resorption in cultured mouse unfractionated bone cells and in rats implanted subcutaneously with devitalized bone particles.
PubMed:Ipriflavone for the treatment of osteoporosis.
PubMed:The future of ipriflavone in the management of osteoporotic syndromes.
PubMed:Design for an ipriflavone multicenter European fracture study.
PubMed:Efficacy of ipriflavone in established osteoporosis and long-term safety.
PubMed:Effect of chronic treatment with ipriflavone in postmenopausal women with low bone mass.
PubMed:Ipriflavone prevents the loss of bone mass in pharmacological menopause induced by GnRH-agonists.
PubMed:In vitro and in vivo effects of ipriflavone on bone formation and bone biomechanics.
PubMed:Ipriflavone inhibits bone resorption in intact and ovariectomized rats.
PubMed:Natural and synthetic isoflavones in the prevention and treatment of chronic diseases.
PubMed:Ipriflavone: background.
PubMed:Ipriflavone: Background
PubMed:Ipriflavone prevents radial bone loss in postmenopausal women with low bone mass over 2 years.
PubMed:Miscellaneous and experimental agents.
PubMed:Ipriflavone does not alter bone apatite crystal structure in adult male rats.
PubMed:Current therapies and future directions in osteoporosis management.
PubMed:[Effects of ipriflavone on bone loss induced by GnRH analog].
PubMed:Novel ipriflavone receptors coupled to calcium influx regulate osteoclast differentiation and function.
PubMed:Inhibition of parathyroid hormone-stimulated resorption in cultured fetal rat long bones by the main metabolites of ipriflavone.
PubMed:Ipriflavone, an antiostheophorotic agent.
PubMed:Effects of ipriflavone and its metabolites on human articular chondrocytes cultivated in clusters.
PubMed:Increase in femoral bone mass by ipriflavone alone and in combination with 1 alpha-hydroxyvitamin D3 in growing rats with skeletal unloading.
PubMed:Determination of ipriflavone and its synthetic impurities by high-performance liquid chromatography using diode-array detection.
PubMed:Ipriflavone metabolite-III inhibits LPS-induced nitric oxide release from RAW-264.7 cells.
PubMed:Clinical guidelines for the treatment of osteoporosis in Japan.
PubMed:The effect of ipriflavone and its main metabolites on theophylline biotransformation.
PubMed:[Place of ipriflavone in the therapy of osteoporosis].
PubMed:[Overview of clinical studies with ipriflavone].
PubMed:[Pharmacokinetics of ipriflavone].
PubMed:[Metabolism of ipriflavone].
PubMed:[Characterization of ipriflavone structure by instrumental examination].
PubMed:[Forced stability study of ipriflavone].
PubMed:[The ipriflavone story].
PubMed:Effects of ipriflavone and estriol on postmenopausal osteoporotic changes.
PubMed:[Long-term assessment of bone loss in patients treated with GnRH agonists].
PubMed:Similarities and differences between the effects of ipriflavone and vitamin K on bone resorption and formation in vitro.
PubMed:Efficacy of ipriflavone and 1 alpha vitamin D therapy for the cessation of vertebral bone loss.
PubMed:[Advances in the pharmacotherapy of osteoporosis].
PubMed:Ipriflavone improves bone density and biomechanical properties of adult male rat bones.
PubMed:Flavonoids alter bone-remodelling in auditory ossicle organ cultures.
PubMed:Interactions between ipriflavone and the estrogen receptor.
PubMed:[The efficacy of osteoquin in treating the postmenopausal and senile forms of osteoporosis].
PubMed:Metabolic and bone effects after administration of ipriflavone and salmon calcitonin in postmenopausal osteoporosis.
PubMed:[Studies of drugs for osteoporosis (3): synthesis of quinolinone derivatives and their treatment of osteoporosis].
PubMed:Prevention of early postmenopausal bone loss using low doses of conjugated estrogens and the non-hormonal, bone-active drug ipriflavone.
PubMed:[Modification of cortical and trabecular mineral density of the femur, induced by ipriflavone therapy, Clinical results after 12 months].
PubMed:Interaction of theophylline and ipriflavone at the cytochrome P450 level.
PubMed:[Treatment of osteoporosis: current data and prospects].
PubMed:Ipriflavone-treatment of senile osteoporosis: results of a multicenter, double-blind clinical trial of 2 years.
PubMed:Stimulation of human osteoblast differentiation and function by ipriflavone and its metabolites.
PubMed:[Pharmacologic therapy of osteoporosis].
PubMed:New perspectives in the treatment of postmenopausal osteoporosis: ipriflavone.
PubMed:Management of osteoporosis and Paget's disease. An appraisal of the risks and benefits of drug treatment.
PubMed:Effects of KCA-098 on bone metabolism: comparison with those of ipriflavone.
PubMed:[New therapy for osteoporosis].
PubMed:Management of postmenopausal osteoporosis.
PubMed:Ipriflavone prevents the bone mass reduction in premenopausal women treated with gonadotropin hormone-releasing hormone agonists.
PubMed:Binding and bioeffects of Ipriflavone on a human preosteoclastic cell line.
PubMed:[A study of bone mineral density in postmenopausal and senile osteoporosis with vertebral fractures in female].
PubMed:[Therapeutic protocols compared in the treatment of postmenopausal osteoporotic disease].
PubMed:[Experimental study on the effect of ipriflavone against osteoporosis in ovariectomized rats].
PubMed:Effects of 1-year treatment with ipriflavone on bone in postmenopausal women with low bone mass.
PubMed:[Postmenopausal osteoporosis. Current therapy protocols].
PubMed:[Osteoporosis. The recent findings on its etiopathogenesis, diagnosis and therapy. II. Therapy].
PubMed:Ipriflavone directly inhibits osteoclastic activity.
PubMed:Effect of ipriflavone on expression of markers characteristic of the osteoblast phenotype in rat bone marrow stromal cell culture.
PubMed:Efficacy of ipriflavone in the prevention and treatment of postmenopausal osteoporosis.
PubMed:[Comparative study of the in vitro effects of calcitonin, NaF and ipriflavone in cell culture].
PubMed:[Clinical aspects of calcium metabolism disorders of the bone. II. Progress in diagnosis and treatment. 2. Metabolic diseases of the bone: 4) Prevention and treatment of osteoporosis].
PubMed:Ipriflavone: pharmacological properties and usefulness in postmenopausal osteoporosis.
PubMed:New treatment strategies: ipriflavone, strontium, vitamin D metabolites and analogs.
PubMed:Inhibitory effect of ipriflavone on osteoclast-mediated bone resorption and new osteoclast formation in long-term cultures of mouse unfractionated bone cells.
PubMed:Lack of effect of ipriflavone on osteoclast motility and bone resorption in in vitro and ex vivo studies.
PubMed:Effects of ipriflavone administration on bone mass and metabolism in ovariectomized women.
PubMed:[Osteoporosis and fractures: a review of current therapies].
PubMed:[Diagnosis and therapy of osteoporosis].
PubMed:Ipriflavone: new insights into its mechanisms of action on bone remodeling.
PubMed:Ipriflavone influences the osteoblastic phenotype in vitro.
PubMed:[Osteoporosis. Detection, prevention, and treatment].
PubMed:Lack of effect of ipriflavone on osteoclast motility and bone resorption in in vitro and ex vivo studies.
PubMed:[Paget's disease: the prospects with ipriflavone].
PubMed:Lack of any estrogenic effect of ipriflavone in postmenopausal women.
PubMed:Effect of ipriflavone on bone mass in elderly osteoporotic women.
PubMed:Ipriflavone and low doses of estrogens in the prevention of bone mineral loss in climacterium.
PubMed:Effects of ipriflavone on bone mass and calcium metabolism in postmenopausal osteoporosis.
PubMed:Short-term treatment of Paget's disease of bone with ipriflavone.
PubMed:Effects of ipriflavone on bone remodeling in primary hyperparathyroidism.
PubMed:Cytological and ultrastructural investigation on osteoblastic and preosteoclastic cells grown in vitro in the presence of ipriflavone: preliminary results.
PubMed:Ipriflavone: A New Non-Hormonal Therapeutic Agent in Osteoporosis. Satellite symposium proceedings. Florence, Italy, April 24, 1992.
PubMed:Ipriflavone inhibits phosphoinositide hydrolysis and Ca2+ uptake in the osteoblast-like UMR-106 cells.
PubMed:Ipriflavone inhibits osteoclast differentiation in parathyroid transplanted parietal bone of rats.
PubMed:[Randomized comparative study using carbocalcitonin i.m. vs carbocalcitonin nasal spray vs ipriflavone x os in the treatment of post-menopausal osteoporosis].
PubMed:Elevation of serum theophylline levels by ipriflavone in a patient with chronic obstructive pulmonary disease.
PubMed:Ipriflavone inhibits murine osteoclast formation in vitro.
PubMed:Effect of ipriflavone on bone mineral density and calcium-related factors in elderly females.
PubMed:Inhibitory effect of ipriflavone on pit formation in mouse unfractionated bone cells.
PubMed:Effects of ipriflavone on calcitonin synthesis in C cells of the rat thyroid.
PubMed:Histochemical and fine structural study of bone of ipriflavone-treated rats.
PubMed:Stimulatory effect of ipriflavone on formation of bone-like tissue in rat bone marrow stromal cell culture.
PubMed:Effect of ipriflavone and estrogen on the differentiation and proliferation of osteogenic cells.
PubMed:Proceedings from a symposium of basic research on ipriflavone (Osten). Yokohama, Japan. January 18, 1992.
PubMed:Double-blind study on the effectiveness of a bioflavonoid in the control of tinnitus in otosclerosis.
PubMed:[Research on the treatment of secondary hyperparathyroidism as a complication of chronic renal failure].
PubMed:[The effect of conservative and surgical management for secondary hyperparathyroidism and their problems].
PubMed:Effects of ipriflavone and its metabolites on a clonal osteoblastic cell line.
PubMed:A study of the effects of ipriflavone administration on hemodialysis patients with renal osteodystrophy: preliminary report.
PubMed:Steady-state pharmacokinetics of ipriflavone and its metabolites in patients with renal failure.
PubMed:[Osteoporosis in diabetes mellitus].
PubMed:[Pharmacokinetics and metabolism of ipriflavone in humans. I].
PubMed:Metabolic and clinical effects of ipriflavone in established post-menopausal osteoporosis.
PubMed:[Pharmacokinetics and metabolism of ipriflavone in humans. II].
PubMed:Radioimmunoassay of circulating alpha-interferon with reference to aging and osteoporosis.
PubMed:[A new treatment possibility for osteoporosis with osteochin (ipriflavone) tablets].
PubMed:Suppressive effect of ipriflavone on bone depletion in the experimental diabetic rat: dose response of ipriflavone.
PubMed:Mobilization of 85Sr by flavone derivatives (morin and ipriflavone) in normal and pregnant rats.
PubMed:The effect of ipriflavone treatment on osteoporosis induced by immobilization.
PubMed:Effect of ipriflavone on accessory sexual organs and bone metabolism in male rats.
PubMed:Effect of flavonoid on PGE2-induced alterations in percentage collagen synthesis in ossicle organ cultures.
PubMed:[Effects of ipriflavone (TC-80, an anti-osteoporotic drug) on acute and chronic pain].
PubMed:Calcitonin secreting property of ipriflavone in the presence of estrogen.
PubMed:The effect of ipriflavone (TC-80) on bone resorption in tissue culture.
PubMed:Effect of ipriflavone on glucocorticoid-induced osteoporosis in rats.
PubMed:Effect of ipriflavone on the response of uterus and thyroid to estrogen.
PubMed:Effect of ipriflavone on bone changes induced by calcium restricted, vitamin D deficient diet in rats.
PubMed:Disposition of ipriflavone (TC-80) in rats and dogs.
PubMed:Metabolism of ipriflavone (TC-80) in rats.
PubMed:The effect of flavone treatment on human otosclerotic ossicle organ cultures.
PubMed:Experimental studies on the cardiological effects of ipriflavone on the isolated rabbit heart and in rat and dog.
 
Notes:
Feed additive, catabolic agent
Please share your Comments.
Email Address:
Top of Page Home
Copyright © 1980-2021 The Good Scents Company (tgsc) ™ Disclaimer Privacy Policy